<DOC>
	<DOC>NCT00107107</DOC>
	<brief_summary>This is a multicenter, open-label extension study designed to examine the long-term safety of pramlintide treatment in subjects with type 1 diabetes who have successfully completed treatment in the parent study 137-150.</brief_summary>
	<brief_title>Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>The subject has completed the full dosing period in Protocol 137150.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
</DOC>